The Form 4 filing, a report of an insider's stock trades, was filed on November 18, 2026. It covers sales from November 16 through November 17, 2026. George L. Sing is listed as a director of Regeneron Pharmaceuticals (REGN).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 2,000 |
| Price | $958.97 |
| Total Transaction Value | $1,917,945.02 |
| Insider | |
| Ticker Symbol | REGN |
| Company | REGENERON PHARMACEUTICALS, INC. |
| Insider Name | SING GEORGE L |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 23,147 |
| Position Size Change | 7.95% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The report lists four sale transactions by one insider, George L. Sing, in a single filing.
What was the average price of the transaction?
The average sale price was $958.97 per share. Before rounding to cents, the reported average was $958.97251 per share. Prices for each individual sale were not available.
How did this transaction affect the insider's holdings?
George L. Sing sold 2,000 shares and reported 23,147 shares owned after the sales. The shares sold made up 7.95% of his reported holdings before the sales. He continued to hold shares after these transactions.
What's the total transaction value?
The four sales had a total value of $1,917,945.02. Separate dollar values for each sale were not available.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Footnote text was not available, so any further terms or explanations remain unknown.
For research purposes only; not investment advice.